In pancreatic cancer cells, activated platelet-derived TGF-β1, rather than direct platelet–tumor cell contacts, promotes MAPK and PI3K/Akt signaling, resulting in the reduction of cisplatin sensitivity in these cells [97]. Here, TGFB1 is linked to neoplasm.